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ABSTRACT 
Autoantibodies to glutamate decarboxylase (GADA) identify individuals at increased risk of 
type 1 diabetes, but many people currently found GADA positive are unlikely to develop 
clinical disease. More specific GADA assays are therefore needed. Recent international 
workshops have shown that reactivity of sera from healthy donors varies according to assay 
type, and indicated that use of N-terminally truncated GAD65 radiolabels in GADA 
radiobinding assays is associated with higher specificity.  To determine whether a 
radiobinding assay using radiolabeled GAD65(96-585) identified individuals at higher 
diabetes risk, samples from recent-onset patients and GADA positive first-degree relatives 
participating in the Bart’s-Oxford type 1 diabetes family study were re-assayed with full-
length or N-terminally truncated GAD using the NIDDK harmonized protocol. The 
sensitivity in patients was the same with both labels, but fewer relatives re-tested positive 
with truncated GAD. Among relatives who progressed to diabetes, similar proportions were 
GADA positive when tested with either label, but because of their higher specificity the 
cumulative risk of diabetes was higher in those with autoantibodies to GAD65(96-585). 
Autoantibodies to GAD65(96-585) in relatives are more closely associated with diabetes risk 
than those to full-length GAD, suggesting assays using N-terminally truncated GAD should 
be used to select participants for intervention trials. 
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Autoantibodies to glutamate decarboxylase (GADA) are the most widely used marker of type 
1 diabetes. They are a mainstay of diabetes prediction and recruitment to therapeutic 
intervention trials as well as being used for disease characterization (1). However, many 
individuals found GADA positive with current assays are unlikely to progress to type 1 
diabetes.  Improved discrimination of diabetes risk can be achieved by testing for multiple 
islet autoantibodies, but the development of more disease-specific GADA assays that enable 
more efficient screening for type 1 diabetes is a high priority (2). 
 
Recent international islet autoantibody workshops revealed systematic differences in 
reactivity between ELISAs and radiobinding assays (RBAs), which suggested that the 
performance of many RBAs may be improved by the use of the N-terminally truncated 
radiolabel 
35
S-GAD65(96-585) (3). We therefore assessed the ability of a RBA using the 
truncated GAD label to identify patients with recent-onset type 1 diabetes and to discriminate 
diabetes progression in first-degree relatives (FDRs) of type 1 diabetes patients in comparison 
with an assay using full-length GAD65. 
 
RESEARCH DESIGN AND METHODS 
Patients with recent onset type 1 diabetes    
To determine the diabetes sensitivity of autoantibodies to the different GAD constructs, sera 
from 147 patients (89 male and 58 female, median age 11.6 years, range 1.3 to 21 years) with 
recent onset type 1 diabetes (median diabetes duration 1 day, range -7 to 90 days) were 
randomly selected from a well-characterized cohort (4) and assayed for GADA(1-585) and 
GADA(96-585). 
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First-degree relatives of type 1 diabetes patients previously screened for GADA. 
Sera were available from 283 relatives (139 male and 144 female) previously found GADA 
positive with a local RBA using 
35
S labelled full-length GAD65, after screening of 4470 FDRs 
(2121 male and 2349 female) in the Bart’s-Oxford (BOX) family study (5). These GADA 
positive relatives were followed prospectively for disease development by annual 
questionnaire (median follow-up to last contact or diabetes diagnosis, 14 years; range 0.2–
27.7 years; median age, 31.4 years; range 1.3–57.4 years). A subset of 459 (227 male and 232 
female) of the first available samples from the 4187 BOX relatives who screened negative 
with the local GADA assay was randomly selected for re-assay for GADA(1-585) and 
GADA(96-585). This subset was enriched with 31 of 179 screen-negative relatives who 
progressed to diabetes (Table 1). Local radiobinding assays were used to measure 
autoantibodies to IA-2 and insulin (5) on all relatives and ZnT8A (6) on those relatives who 
initially screened positive for GADA or who had progressed to diabetes.  
 
Autoantibody assays 
Sera from patients and relatives were assayed for GADA using the NIDDK harmonized assay 
protocol (7) with 
35
S methionine labeled antigens made by in vitro transcription and 
translation of both N-terminally truncated GAD65(96-585) and full-length GAD65 encoded in 
the pTNT plasmid vector (Promega, Madison, WI, USA) (3). To localize N-terminal epitopes 
more precisely, a subset of samples from the screen-positive FDRs was also re-assayed for 
GADA using 
35
S labeled GAD65(46-585). A methionine residue was added to both truncated 
antigens to allow transcription. Samples were considered positive if ≥ 97.5
th
 percentile of 222 
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healthy schoolchildren (8); 13.5 DK units/ml for GADA(1-585), 12.8 DK units/ml for 
GADA(96-585) and 25.4 DK units/ml for GADA(46-585). Using these thresholds, the 
sensitivity of the GADA(1-585) assay was 72% at a specificity of 92% and the sensitivity of 
the GADA(96-585) assay was 70% at 99 % specificity in the Islet Autoantibody 
Standardization Program (IASP) 2013 workshop. The inter-assay CV of GADA(1-585) was 
12.9 % at 53 DK units/ml (n=32). The inter-assay CV of GADA(96-585) was 13.0 % at 59 
DK units/ml (n=32). 
 
HLA genotyping 
HLA class II genotyping was available on 209 (74%) of the 283 GADA positive relatives. 
HLA class II DRB1, DQA1, and DQB1 analysis was performed on blood and mouth swab 
DNA with sequence-specific primers as previously described (9). Haplotypes were 
established based on common patterns of linkage disequilibrium.  
 
Data analysis 
Categorical variables were compared using the χ
2
 test. Genetic risk was analyzed according to 
the high risk haplotypes DRB1*03-DQA1*0501- DQB1*0201 (DR3-DQ2) and DRB1*04-
DQA1*0301-DQB1*0302 (DR4-DQ8) as well as the protective haplotype DRB1*02-
DQB1*0602 (DR2-DQ6). Other haplotypes were classified as X. Survival analysis was 
carried out using Kaplan–Meier methods and log-rank testing (Mantel–Cox) used to compare 
survival between groups. For all analyses, a two-tailed P-value of 0.05 was considered 
significant. The area under the ROC curve (ROC-AUC) with 95% confidence interval (CI) 
was calculated assuming a nonparametric distribution of results using R software. Other 
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statistical analyses were performed using the Statistics Package for Social Sciences Version 
21 (IBM, New York, USA). 
 
RESULTS 
Patients with recent onset type 1 diabetes 
Using thresholds equivalent to the 97.5
th
 percentile in schoolchildren, the sensitivity of 
GADA(96-585) was identical to GADA(1-585) in patients with recent onset type 1 diabetes 
(Figure 1a). Of 147 patients, 117 (80%) were positive for GADA(96-585), and 117 positive 
for GADA(1-585).  One hundred and sixteen patients (79%) had autoantibodies to both GAD 
constructs and there was excellent correlation between the levels of GADA (96-585) and 
GADA (1-585) (r = 0.99, p<0.001, Figure 2a). The ROC-AUCs based on the patients and 
schoolchildren were also very similar for GADA(1-585) and GADA(96-585); 0.94, 95% CI: 
0.91-0.97 and 0.93, 95% CI: 0.9-0.96, respectively (Figure 3). 
 
Relatives who previously screened GADA positive 
Of 283 relatives previously found positive for GADA using the local RBA, 259 (92%) were 
positive on re-assay using the harmonized assay protocol with 
35
S-GAD65(1-585), 206 (73%) 
with 
35
S-GAD65(96-585) and 195 (69%) with both labels (Figure 1b). Of 70 relatives who 
progressed to diabetes, 66 (94%) were positive for GADA(1-585), 63 (90%) positive for 
GADA(96-585) and 61 (87%) positive for both specificities. Of 76 relatives previously found 
positive for GADA who had at least one additional islet autoantibody, 73 (96%) were 
positive for GADA(1-585), 70 (92%) were positive for GADA(96-585) and 69 were positive 
for both specificities.  Of these multiple antibody positive relatives, 39 (53%) with GADA(1-
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585) and 38 (54%) with GADA(96-585) developed diabetes. Of 207 relatives with no 
additional autoantibodies, 187 (90%) were positive for GADA(1-585) compared to 136 
(66%) for GADA(96-585) (p<0.001). There was a good correlation between the levels of 
GADA(1-585) and GADA(96-585) in sera from the GADA positive relatives (r=0.96, 
p<0.001) (Figure 2b). Of 64 relatives positive for GADA(1-585), but negative for GADA(96-
585), 38 (59%) had GADA(1-585) levels of less than 50 DK units/ml, a level found in 27 of 
the 147 (18%) recent-onset patients. Deletion of amino acids 46 to 95 of GAD65 was 
important in improving specificity with little loss of sensitivity; of the 64 samples with 
GADA(1-585) alone, 49 (77%) were positive for GADA(46-585) of whom only 4 (8%) 
developed diabetes.  
 
Kaplan-Meier survival analysis showed that positivity for GADA(96-585) identified relatives 
positive for autoantibodies to full-length GAD who were at increased risk of diabetes 
progression (Figure 4, p<0.001). Of the 11 relatives who re-screened positive only for 
GADA(96-585), one had additional autoantibodies (IAA and IA-2A), but was lost to follow-
up after 4 years, while two others developed diabetes after 5 and 6 years of follow-up. Of 160 
relatives carrying at least one HLA risk haplotype who re-screened positive for GADA(1-
585), 129 (81%) were positive for GADA(96-585), compared with 18 of 35 (51%) with no 
HLA risk haplotype (p<0.001). Furthermore, GADA(96-585) were less common in GADA 
positive relatives carrying protective haplotypes; of 13 relatives carrying HLA-DQ6, 12 were 
positive for GADA(1-585), but only 3 were positive for GADA(96-585) (p=0.001). 
 
Relatives who previously screened GADA negative 
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Of the 428 relatives who remained non-diabetic during follow-up who previously screened 
negative with the original GADA assay, 7 (1.6%) were positive for GADA(1-585) alone, 2 
(0.5%) were positive for GADA(96-585) alone and 4 (0.9%) positive for both. Of the 31 
relatives who progressed to diabetes, but screened negative for GADA with the original 
assay, none were positive for GADA(1-585) and one was positive for GADA(96-585). 
 
DISCUSSION 
GADA measured using N-terminally truncated antigen achieved the same sensitivity in 
recent onset patients as the assay using full-length GAD65, while those relatives having 
autoantibodies to GAD65(96-585) were at higher risk of progression than those with 
autoantibodies to full-length GAD alone. Survival analysis showed that very few GADA 
positive relatives without autoantibodies to GAD65(96-585) progressed to diabetes within 20 
years. Furthermore, only a minority of GADA positive relatives who carried protective HLA 
haplotypes were found positive when using the N-terminally truncated label. 
 
Birth cohort studies of relatives of type 1 diabetes patients have shown that autoantibody 
epitope reactivity typically spreads from the C-terminal and middle (PLP) regions to the N-
terminal domains of the molecule (10; 11). Autoantibodies to the N-terminal region normally 
constitute a relatively minor component of GAD autoreactivity and in isolation have little 
association with progression to diabetes (12). Our data would support this observation, since 
most samples from relatives who progressed showed similar antibody binding and levels with 
full-length GAD65 and GAD65(96-585) (Figure 2b). Furthermore, the majority (59%) of 
relatives found positive for GADA(1-585), but negative for GADA(96-585) had relatively 
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low levels of GADA (<50 DK units/ml), consistent with a less vigorous autoimmune 
response in these individuals. This explains why sensitivity in recent onset patients was 
maintained, but most relatives carrying protective haplotypes and only a small proportion of 
relatives with multiple islet autoantibodies were found negative when GADA were measured 
using the truncated construct.  
 
Several groups have investigated the effect of N-terminal truncations of GAD65 on the 
disease sensitivity of GADA. Deletion of the first 194 amino acids did not cause decreased 
binding by 8 prediabetic/diabetic sera (13), while in agreement with our findings an assay 
using 
125
I labeled GAD65(46-585) performed similarly to an assay using 
35
S labeled full-
length GAD65 (14). However, to our knowledge, this is the first study to show improved 
discrimination of diabetes progression using an N-terminally truncated GAD65 label. The use 
of truncated antigens is established practice for the measurement of autoantibodies to islet 
antigen-2 (IA-2) and zinc transporter 8 (ZnT8), since the main diabetes-relevant epitopes are 
located in the intracellular portion of IA-2 and carboxy terminal region of ZnT8 (15; 16). If 
confirmed in other populations, including young children, our finding suggests that screening 
strategies to identify individuals at high risk of diabetes should use GADA RBAs based on 
N-terminally truncated protein. 
 
Although fewer autoantibodies to disease irrelevant GAD65 epitopes were detected using the 
N-terminally truncated label, the Kaplan-Meier survival curve suggests that less than half of 
GADA(96-585) positive relatives will develop diabetes within 25 years (Figure 4). N-
terminally truncated GADA associated with autoantibodies to other islet antigens, but could 
not discriminate risk of progression within multiple antibody positive relatives. Further 
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improvements in assay specificity are therefore desirable. This may be achieved by more 
radical N-terminal deletions, if additional diabetes irrelevant epitopes are disrupted without 
affecting binding to diabetes relevant epitopes. Our addition of an N-terminal methionine to 
GADA(96-585) to allow protein expression is unlikely to have affected antibody binding as it 
is neither highly charged nor bulky. Inclusion of affinity measurements may also help to 
identify GADA positive individuals at increased risk of diabetes progression (12; 17). The 
potential for truncated GAD65 labels to identify patients with slow onset autoimmune diabetes 
in adults with a clinical presentation of type 2 diabetes, also needs to be investigated. A 
previous study using GAD65/GAD67 chimeras rather than truncated GAD65 found no 
difference in the time to insulin requirement between those patients with or without N-
terminal autoantibodies (18). 
 
Radiobinding assays are still widely used for prediction and characterization of type 1 
diabetes despite the advent of high quality alternative assay formats such as the bridging 
ELISA (19) and electrochemiluminescence assay (20). Advantages of RBAs include their 
relatively low cost, high sensitivity, good flexibility, small serum volume requirement, and 
proven track-record in diabetes prediction as well as the wide availability of equipment and 
reagents. However, a major shortcoming of GADA RBAs has been their relative lack of 
specificity. We have demonstrated that use of an N-terminally truncated GAD65 label can 
improve the disease specificity of the GADA assay without loss of sensitivity in patients and 
identify GADA positive relatives at higher risk of progression. As recruitment of high-risk 
relatives to therapeutic intervention trials normally includes initial testing for GADA, these 
findings strongly suggest that adoption of autoantibody assays using N-terminally truncated 
GAD65 would greatly improve screening efficiency for future studies aimed at preventing 
type 1 diabetes. 
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 GADA positive GADA negative 
 Non-progressors Progressors Non-progressors Progressors 
n 213 70 428 31 
Male 102 37 204 23 
Age (years) 
31.5 
(1.3 to 57.4) 
30.9 
(1.6 to 52.9) 
32.7 
(1.7 to 57.3) 
39 
(1.4 to 56) 
Age at diagnosis 
(years) 
- 
38 
(3.2 to 69.8) 
- 
52 
(3.3 to 68.5) 
Follow-up (years) 
14.9 
(0.6 to 27.7) 
7.2 
(0.2 to 24.2) 
15.2 
(0 to 27.6) 
12.3 
(1.2 to 23.8) 
Additional 
autoantibodies 
37 39 11* 4 
IA-2A 13 22 0 2 
IAA 23 23 11 3 
ZnT8A 19 27 - 1 
Table 1. Characteristics of FDRs participating in the BOX family study whose samples were 
originally screened for GADA using a local assay and were re-assayed using the standard 
method with 
35
S-labeled GAD65(1-585) and GAD65(96-585). Additional autoantibodies from 
IA-2A, IAA and ZnT8A. 
*not assayed for ZnT8A 
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Figure legends 
Figure 1. Scheme showing the selection of samples and results for (a) healthy schoolchildren 
and patients with newly diagnosed type 1 diabetes or (b) BOX relatives, following re-assay 
with the harmonized protocol using either 
35
S labeled GAD65(1-585) or GAD65(96-585). The 
same proportion of patients was found positive for GADA(96-585) as for GADA(1-585). 
However, fewer relatives previously found GADA positive with the local assay were found 
positive on re-assay for GADA(96-585) than for GADA(1-585) (p<0.001). 
Figure 2. Plot of GADA(96-585) against GADA(1-585) results for (a) 147 patients with 
recent-onset type 1 diabetes and (b) 283 FDRs from the BOX family study who previously 
screened GADA positive with a local RBA. Inset is an expanded plot of results for samples 
with GADA(1-585) levels up to 100 DK units/ml. Relatives who progressed to diabetes 
within 10 years are indicated with closed diamonds, those who progressed after 10 years with 
closed triangles and relatives who did not progress by open circles. Thresholds for the assays 
are given by the dotted lines and equivalent levels of both autoantibodies are indicated by the 
dashed lines. Correlation of GADA(96-585) with GADA(1-585) was excellent for patients (y 
= 1.04x - 4.79, R = 0.99) and very good for FDRs (y = 1.16x - 14.84, R = 0.96), although 
many sera from FDRs found positive for  GADA(1-585) with levels up to 378 DK units/ml 
were found negative for GADA(96-585). 
Figure 3. Receiver Operator Characteristics Curves for GADA(1-585) (bold dashed line) and 
GADA(96-585) (solid line) based on data from 147 patients with newly diagnosed type 1 
diabetes and 222 healthy schoolchildren. The autoantibodies performed similarly; The area 
under the curve (AUC) was 0.94 for GADA(1-585) and 0.93 for GADA(96-585) (p=0.28). 
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The partial AUC (pAUC) calculates areas at specificities above 90% (within the grey box) 
and was 0.081 for GADA(1-585) and 0.080 for GADA(96-585) (p=0.69). 
Figure 4. A Kaplan-Meier survival curve for FDRs positive for GADA(1-585) according to 
positivity for GADA(96-585). GADA(96-585) identified FDRs at increased risk of diabetes  
progression; few FDRs positive for GADA(1-585), but negative for GADA(96-585) 
developed diabetes within 20 years of follow-up.  
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GADA (96-585) +ve n 195 163 118 61 33 8 
GADA (96-585) -ve n 64 60 55 40 27 6 
p<0.001 
 
 
 
GADA(96-585) 
-ve 
GADA(96-585) 
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